Symbols

OGN

Organon·NYSE

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Sell"

MACD Golden Cross

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About OGN

Organon & Co.

A pharmaceutical company that specializes in the field of reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia

Industry

Pharmaceutical

Established Date

03/11/2020

Listing Date

06/03/2021

Exchange

New York Stock Exchange

Full-time Employees

10,000

Fiscal Year Ends

12-31

Website

www.organon.com

Security Type

Common stock

Office address

30 Hudson Street, Floor 33, Jersey City, New Jersey, 07302

Business

Introduction

Organon & Co., a company incorporated in Delaware on March 11, 2020. The company is a global healthcare company with a mission to deliver impactful medicines and solutions to make every day healthier. With a portfolio of more than 70 products in women's health and general medicines, including biosimilars, the company focuses on meeting health needs that have a unique, disproportionate or differential impact on women, while expanding access to essential treatments in more than 140 countries and regions.

Company Financials

EPS

OGN has released its 2025 Q4 earnings. EPS was reported at 0.63, versus the expected 0.76, missing expectations. The chart below visualizes how OGN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OGN has released its 2025 Q4 earnings report, with revenue of 1.51B, reflecting a YoY change of -5.34%, and net profit of -205.00M, showing a YoY change of -288.07%. The Sankey diagram below clearly presents OGN's revenue sources and cost distribution.